Details of the Drug Combinations

General Information of This Drug (ID: DMINAG4)

Drug Name

Meglumine antimoniate DMINAG4

Synonyms

Glucantime; Methylglucamine antimonate; Meglumine antimonate; Protostib; 133-51-7; meglumine antimoniate; N-Methylglucamine antimonate; UNII-75G4TW236W; 2168-RP; EINECS 205-108-3; N-Methylgluamine Antimoniate; 1-Deoxy-1-(methylamino)glucitol antimonate(V); 75G4TW236W; D-Glucitol, 1-deoxy-1-(methylamino)-, trioxoantimonate(1-); 1-Deoxy-1-(methylamino)-D-glucitol, compound with antimonic acid (1:1); D-Glucitol, 1-deoxy-1-(methylamino)-, compd. with antimonic acid (1:1); Glucitol, 1-deoxy-1-(methylamino)-, compd. with antimon

Indication

Disease Entry	ICD 11	Status	REF
Leishmania braziliensis infection	1F54.2	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Meglumine antimoniate + Pentoxifylline	DCBLTV8	Pentoxifylline	Cutaneous Leishmaniasis	[2]
Meglumine antimoniate + Pentoxifylline	DCBO7UC	Pentoxifylline	Leishmaniasis	[3]
Meglumine antimoniate + Tofacitinib	DCPY27I	Tofacitinib	Cutaneous Leishmaniasis, American	[4]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01464242) Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
3	ClinicalTrials.gov (NCT02530697) The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
4	ClinicalTrials.gov (NCT06011343) Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis